|
|
|
|
|
|
Sponsored by: |
Alcon Research |
Information provided by: | Alcon Research |
ClinicalTrials.gov Identifier: | NCT00708422 |
The objective of this study is to examine the affect on tear film break up time (TBUT) of changing patients on Xalatan® therapy to TRAVATAN Z®.
Condition | Intervention | Phase |
Glaucoma |
Drug: Travoprost eye drop Drug: Latanoprost |
Phase IV |
Genetics Home Reference related topics: | early-onset glaucoma |
MedlinePlus related topics: | Glaucoma |
Drug Information available for: | Latanoprost Tetrahydrozoline Tetrahydrozoline hydrochloride Travoprost |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Parallel Assignment |
Estimated Enrollment: | 110 |
Study Start Date: | July 2008 |
Estimated Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Active Comparator
Travoprost BAK-free
|
Drug: Travoprost eye drop
Ophthalmic solution
|
2: Active Comparator
Latanoprost
|
Drug: Latanoprost |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Alcon ( Mark Jasek ) |
Study ID Numbers: | SMA-08-07 |
First Received: | June 30, 2008 |
Last Updated: | July 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00708422 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|